{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T15:29:08Z","timestamp":1770650948205,"version":"3.49.0"},"reference-count":26,"publisher":"S. Karger AG","issue":"2","license":[{"start":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T00:00:00Z","timestamp":1622764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T00:00:00Z","timestamp":1622764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatology"],"published-print":{"date-parts":[[2022]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Background:&lt;\/i&gt;&lt;\/b&gt; Apremilast is an oral phosphodiesterase 4 (PDE4) inhibitor used for the treatment of moderate to severe psoriasis. Long-term data on the effectiveness and drug survival of patients treated with apremilast are limited. &lt;b&gt;&lt;i&gt;Objective:&lt;\/i&gt;&lt;\/b&gt; The aim of this study was to analyze the characteristics, effectiveness, and drug survival of patients treated with apremilast in a real-world setting. &lt;b&gt;&lt;i&gt;Methods:&lt;\/i&gt;&lt;\/b&gt; We conducted a retrospective cohort study of patients with psoriasis who received at least 1 dose of apremilast between 2015 and 2018. We documented sex; age; type, duration, and severity (using Psoriasis Area Severity Index [PASI] and Dermatology Life Quality Index [DLQI]) of psoriasis; comorbidities; previous treatment modalities; adverse events; and reasons for therapy discontinuation. For drug survival, estimates and efficacy analysis with Kaplan-Meier statistics were used. &lt;b&gt;&lt;i&gt;Results:&lt;\/i&gt;&lt;\/b&gt; The drug survival rate of the 93 reviewed patients was 69.5% at 6 months, 34.7% at 12 months, and 25.8% at 24 months after initiating therapy. The median survival duration was 8.0 months. Therapy was discontinued in 66.6 and 27.8% due to loss of efficacy and adverse events, respectively. At 24 months, 35.9% had achieved PASI75 response and 23.7% had achieved PASI90 response. Most observed adverse events were gastrointestinal issues, weight loss, and headache. &lt;b&gt;&lt;i&gt;Conclusions:&lt;\/i&gt;&lt;\/b&gt; Apremilast is an effective and well-tolerated therapy for patients with moderate to severe psoriasis, especially for patients with difficult-to-treat locations and\/or contraindications to other biologics. Furthermore, apremilast was used for patients with a history of nonresponse to biologics and was favored for patients with relatively low PASI (&amp;#x3c;10) and a high DLQI. <\/jats:p>","DOI":"10.1159\/000515763","type":"journal-article","created":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T21:01:41Z","timestamp":1622840501000},"page":"267-275","source":"Crossref","is-referenced-by-count":13,"title":["Long-Term Effectiveness and Drug Survival of Apremilast in Treating Psoriasis: A Real-World Experience"],"prefix":"10.1159","volume":"238","author":[{"given":"Julian","family":"Distel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Cazzaniga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6466-2199","authenticated-orcid":false,"given":"S. Morteza","family":"Seyed Jafari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Emelianov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Schlapbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil","family":"Yawalkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristine","family":"Heidemeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2021,6,4]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61909-7"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.06.057"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.02.026"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.01.052."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.03.049"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14164"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14943"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.03.028"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14832"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14598"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1159\/000445681"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.13152"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13343"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.208"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2018.1525480"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17738"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.171"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.06.035"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12448"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0997"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15104"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14617"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.7861\/fhj.7.1.s47"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16443."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1728253"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1770167"}],"container-title":["Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/515763","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/515763","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T16:37:49Z","timestamp":1745426269000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000515763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,4]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,3,10]]},"published-print":{"date-parts":[[2022,3,14]]}},"URL":"https:\/\/doi.org\/10.1159\/000515763","archive":["Portico"],"relation":{},"ISSN":["1018-8665","1421-9832"],"issn-type":[{"value":"1018-8665","type":"print"},{"value":"1421-9832","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,4]]}}}